ClinicalTrials.gg
Not yet recruitingNCT07862673HiPLARSUpdated Oct 23, 2026

Efficacy of a Novel High Intensive Percutaneous Tibial Nerve Stimulation on Faecal Incontinence in Patients With Low Anterior Resection Cancer Syndrome After Rectal Cancer Surgery

An interventional study of Percutaneous Tibial Nerve Stimulation in Faecal Incontinence With Faecal Urgency, Rectal Cancer and Radiotherapy Side Effects, sponsored by Region Skane. Not yet recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Region Skane · Not applicable, Interventional, and Treatment

How we know

Updated Oct 23, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Rectal Neoplasms with a site in Sweden — 15 open to participants now, 22 under way, 4 of them phase 3. Rectal Neoplasms · Sweden.

Planned enrollment
30th of 40
60 · median 233
Started
2026
the only one that year
No phase
20 of 64
10 open now
Primary completion
2029-10
later than 19 of 21 live
Registered
64th of 64
by date
Lead sponsor
3 of 64
Region Skane

Among the 64 studies in Rectal Neoplasms with a site in Sweden, this one is the 30th largest by planned enrollment of the 40 interventional ones that give a count, is the only one that started in 2026, is one of 20 with no phase, reaches primary completion later than 19 of the 21 other live ones, and was the 64th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

15 of the 64 studies in Rectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Rectal Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

This study aims to assess and evaluate the clinical efficacy of an intensified form of Percutaneous tibial nerve stimulation (PTNS) compared to standard conservative treatment for low anterior resection syndrome (LARS). A syndrome with symptoms such as faecal incontinence (FI), urgency to defecate and frequent bowel movements. Focus will be mainly on patients with significant faecal incontinence.

Participants will be randomized into 2 groups: Standard Care with bowel regulation or to High Intensive PTNS for 6 weeks.

Every treatment session will be at the clinic and take 30 minutes.

Standard care PTNS participants will have nurse contact once per week for 6 weeks

High Intensive PTNS participants will start with 5 sessions per week, which will the be phased out to 2 sessions per weeks during the 6 week period.

Follow up visits to the clinic will be at 3, 6 and 12 months after completion of study.

Patients in the Standard group whose symtoms have not improved significantly, will be given the option to try the High Intensive treatment option.

Read the detailed description

The HIPLARS study is a Swedish clinical research project investigating whether an intensive form of Percutaneous Tibial Nerve Stimulation (PTNS) can improve faecal incontinence (FI) in patients who develop Low Anterior Resection Syndrome (LARS) after rectal cancer surgery. LARS commonly causes frequent bowel movements, urgency, and faecal incontinence, which can significantly reduce quality of life.

All participants receive the current standard treatment for FI, including bowel management, pelvic floor exercises, biofeedback, and, if needed, mini-enemas. The study compares this standard treatment with an intensified PTNS treatment, a minimally invasive nerve stimulation therapy that may provide longer-lasting symptom relief. Participants whose symptoms persist after six months may also be offered PTNS.

The study will include approximately 60 participants across three Swedish clinics and lasts 12 months. Depending on the assigned study group, participants will attend 17-29 clinic visits and receive 12-24 PTNS treatment sessions, each lasting about 30 minutes. Assessments include medical examinations, ultrasound, questionnaires, quality-of-life surveys, and bowel diaries.

Participation is voluntary, and participants may withdraw at any time without affecting their future medical care. Researchers may also end participation for medical reasons or if study procedures are not followed.

PTNS is already an established treatment with a low risk of side effects. Possible risks include mild discomfort from the needle insertion and occasional minor bleeding at the insertion site. Serious side effects are uncommon.

Personal and medical information will be kept confidential, stored securely, and handled in accordance with GDPR and Swedish law. Study results may be published, but participants' identities will remain confidential.

The study is conducted by the Pelvic Floor Centre, Department of Surgery, Skåne University Hospital (SUS) Malmö, has been approved by the Swedish Ethical Review Authority, and is covered by standard patient and pharmaceutical insurance. Participants can contact the study team at any time with questions or concerns.

03

Conditions studied

  • Faecal Incontinence With Faecal Urgency
  • Rectal Cancer
  • Radiotherapy Side Effects
  • Low Anterior Resection Syndrome (LARS>20)

Keywords

  • Rectal Cancer
  • Percutaneous Tibialis Nerve Stimulation (PTNS)
  • Low Anterior Resection Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The presence of Faecal incontinence sufficiently severe to warrant intervention
  • Have undergone low anterior resection and with low anterior resection syndrome (LARS) score >20
  • The presence of incontinence for >6 months before inclusion in the study, failure of conservative treatment (e.g. fiber plus loperamide, biofeedback, bulking agents or TAI - transanal irrigation).

Exclusion criteria

Exclusion Criteria:

  • Inability to be able to communicate both verbally and in written Swedish language
  • Patients with neurological diseases such as multiple sclerosis, diabetic neuropathy and Parkinson's disease.
  • Medical conditions precluding stimulation, for example bleeding disorders, novel oral anticoagulants (NOACs), cardiac pacemaker or implantable defibrillator, peripheral vascular disease or ulcer, lower leg cellulitis.
  • Severe cardiopulmonary disease with severe distal venous insufficiency, local skin lesion, low molecular heparin or
  • Chronic bowel diseases such as inflammatory bowel disease with chronic uncontrolled diarrhoea
  • Pregnancy or intention to become pregnant
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • No intervention
    Standard Care

    Conservative treatment for faecal incontinence. Mainly bowel regulation

  • Experimental
    Percutaneous Tibial Nerve Stimulation

    24 treatment sessions av Percutaneous Tibial Nerve Stimulation

    Procedure: Percutaneous Tibial Nerve Stimulation

Interventions

  • ProcedurePercutaneous Tibial Nerve Stimulation

    A total of PTNS 24 sessions, with 5 PTNS sessions per week (30 min each) for 4 weeks, thereafter 2 sessions per week for 2 weeks.

    Also known as: PTNS

06

What researchers measure

Primary outcomes

  1. Change in Low Anterior Resection Syndrome Score

    The primary outcome classifies patients as responders or non-responders, with a responder defined as someone having a change of the LARS score from Major LARS to Minor or No LARS

    Time frame: Outcome measures to be assessed at baseline, after 6 weeks, 3 months and 6 month treatment being the primary end point.

Secondary outcomes

  1. Improvement or change of at least 50 per cent in the number faecal incontinence episodes

    An achievement of ≥ 50% change in weekly faecal incontinence episodes (FIEs) for secondary outcome

    Time frame: Outcome measures to be assessed at baseline, after 6 weeks, 3 months and 6 month treatment being the primary end point.

07

Study locations

1 site
  • Department of Surgery. Pelvic Floor Centre
    Malmö, Skåne County 20502, Sweden
    • Victor J Verwaal, Associate Professor of Surgery · Contactvictor.verwaal@med.lu.se · +46 40333019
    • Mikael Ekelund, Associate Professor of Surgery · Contactmikael.ekelund@skane.se · +46 46171896
    • Louis B Johnson, Associate Professor of Surgery · Principal investigator
    • Peder N Rogmark, MD PhD · Sub investigator
    • Ursula A Fält, MD PhD · Sub investigator
    • Alejandro Lusilla Lopez, MD · Sub investigator
    • Sara E Strandberg, Registered Specialist Nurse · Sub investigator
    • Caroline Nilsson, Registered Research Nurse · Sub investigator
    • Maria Torper, MD · Sub investigator
    • Martin Lindsten, MD · Sub investigator
08

References and documents

Related links

Individual participant data

Plan to share: No — Basically the Ethical clearance for the study does not accomodate sharing of IPD. Further, the study focuses mainly on cancer patients which is a sensitive patient group with regards to symtoms being examined in the study.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2029, 35 months later.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 35 months is below that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 7, 2026
StartEst.
Oct 5, 2026
Primary completionEst.
Oct 1, 2029
CompletionEst.
Dec 1, 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
Revised in 2 updates
What changed on Oct 16, 2026
  • EditedReductionChange in Low Anterior Resection Syndrome ScoreTime frame: Outcome measures to be assessed at baseline, after 6 weeks, 3 months and 6 month treatment being the primary end point.
What changed on Oct 23, 2026
  • DescriptionChange in Low Anterior Resection Syndrome Score: how it is measured was reworded
across 2 updates, Oct 16, 2026 – Oct 23, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedImprovement or reductionchange of at least 50 per cent in the number faecal incontinence episodesTime frame: Outcome measures to be assessed at baseline, after 6 weeks, 3 months and 6 month treatment being the primary end point.
Oct 16, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 3 updates
  1. Oct 23, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange in Low Anterior Resection Syndrome Score: how it is measured was reworded
  2. Oct 16, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedReductionChange in Low Anterior Resection Syndrome ScoreTime frame: Outcome measures to be assessed at baseline, after 6 weeks, 3 months and 6 month treatment being the primary end point.
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedImprovement or reductionchange of at least 50 per cent in the number faecal incontinence episodesTime frame: Outcome measures to be assessed at baseline, after 6 weeks, 3 months and 6 month treatment being the primary end point.
    + 3 other changes: index terms, conditions and criteria formatting
  3. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862673
Lead sponsor
Region Skane
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Oct 5, 2026 (estimated)
Primary completion
Oct 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

Louis B Johnson, Associate Professor of Surgery
Contact
louis.johnson@med.lu.se
+46 704951997
Alejandro Lusilla Lopez, MD Consultant
Contact
alejandro.lusilla_lopez@med.lu.se
+46 761028020
Louiis B Johnson, Associate Professor of Surgery
principal investigator · Region Skåne - University of Malmö / Lund

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion